The Benefits of Taking Your Career to a Growth Stage Biotech

Published on :

Over the next few years, thousands of new positions in the biopharma and life sciences industry are expected to open up across the BioHealth Capital Region and the greater Philadelphia area known as Cellicon Valley.

Whether you are fresh out of the university or a seasoned veteran, many job seekers question whether or not they should aim for large biopharmaceutical companies, such as AstraZeneca, Pfizer or GlaxoSmithKline, or look at nimble, growth-stage companies, such as American Gene Technologies, Vita Therapeutics, or BioFactura, Inc., which is currently scaling their cGMP and Quality operations.

5 Questions with James Bucky Polk, Chief Commercial Officer, Scientific Bioprocessing

Published on :

After 25 years with an extensive track record of success in the Medical Device space, Bucky Polk joined SBI in July 2020. He is a well-rounded executive with a vast collection of skills and experiences. Colleagues and customers have said that his authenticity, candor, and ability to connect with people are what set him apart. In his most recent role for Philips, he was responsible for the customer engagement of the most influential global Interventional Cardiologists, Vascular Surgeons, and Interventional Radiologists.

5 Questions with Raj Vora, PE, Life Sciences Core Market Leader, DPR Construction

Published on :

Raj Vora is a Life Sciences Core Market Leader, Responsible for business growth, technical expertise, and account management of the DPR Construction’s life sciences portfolio in the region through project and customer development or project-specific roles. Focused on cGMP manufacturing facilities primarily in the cell and gene therapy market and involved in lab, containment, and other research projects.

TCR² Therapeutics Establishing 85,000 Square Foot Cell Therapy Manufacturing Facility in Maryland

Published on :

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland.

5 Questions with Danielle Kalkofen, Quality Control Scientist, Vigene Biosciences

Published on :

Danielle Kalkofen is a molecular cell biologist and biochemist with 15 years of industry and academic experience. In 2015, she turned her focus to biological assay development, leading cross-functional teams to develop, validate, and commercialize new pathogen detection assay products.

5 Questions with Akunna Iheanacho, Ph.D., Scientific Director, Texcell North America, Inc.

Published on :

Akunna Iheanacho, Ph.D., is the Scientific Director at Texcell North America, Inc., where she provides technical and scientific direction for novel assay development, virus purification efforts, and viral safety testing. She also serves as a Study Director for viral clearance studies. She is a subject matter expert with broad biotechnology experience and expertise in areas that include process development for large-scale cGMP manufacture of vaccines, AAV gene therapies, and biopharmaceutical purification.

Vigene Biosciences Plans Major Expansion in Maryland, Adding up to 245 Jobs

Vigene Biosciences Expansion 245 New Jobs
Published on :

Vigene, a gene therapy development company, said it intends to lease a 52,000 square-foot manufacturing space at 14200 Shady Grove Road that will nearly double the company’s existing manufacturing footprint. The new space is in addition to its existing headquarters, R&D, and manufacturing locations that opened in Rockville last year. The additional space from the new facility will allow the company to expand its current headcount of 125 by the addition of 245 more employees.

5 Questions with Ben Woodard, Business Development Partner, ABIO

Published on :

Ben Woodard is a Business Development Partner with ABIO and a recent retiree of the University of Maryland, where he was the Executive Director of the Biotech Research Program (BREP) for over a decade.